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Abstract  
Inkjet–printing technology was used to apply biodegradable and biocompatible polymeric 
coatings of poly(D, L lactide) with the antiproliferative drugs simvastatin (SMV) and 
paclitaxel (PCX) on coronary metal stents. A piezoelectric dispenser applied coating patterns 
of very fine droplets (300 xL) and ink jetting was optimized to develop uniform, accurate and 
reproducible coatings of high yields on the stent strut. The drug loaded polymeric coatings 
were assed by scanning electron microscopy (SEM), atomic force microscopy (AFM) and 
transition thermal microscopy (TTM) where a phase separation was observed for SMV/PLA 
layers while PCX showed a uniform distribution within the polymer layers.  
Cytocompatibility studies of PLA coatings showed excellent cell adhesion with no decrease 
of cell viability and proliferation. In vivo stent implantation studies showed significant intra 
stent restenosis (ISR) for PXC/PLA and PLA plain coatings similar to marketed Presillion 
(bare metal) and Cypher (drug eluting) stents. The investigation of several cytokine levels 
after seven days of stent deployment showed no inflammatory response and hence no in vivo 
cytotoxicity related to PLA coatings. Inkjet printing can be employed as a robust coating 
technology for the development of drug eluting stents compared to the current conventional 
approaches. 
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Introduction 
In the last twenty years drug eluting stents (DES) have revolutionized interventional 
cardiology and have been widely adopted due to the improvements in angiographic and 
clinical outcomes.
1, 2
  DES have shown better performance compared to bare metal stents 
(BMS) and demonstrated significantly lower late loss, target vessel, revascularization and 
major adverse cardiovascular events in follow up studies  in 6 and 12 months.
3
 Although the 
risks of mortality associated with DES and BMS has been shown to be similar the clinical 
effect of DES appears to be superior.
4
  
For DES, an active pharmaceutical ingredient (API) along with a suitable polymer, which 
serves as a carrier to control the release of the drug, is coated on the stent strut. After 
implantation the API is released in order to inhibit neointimal cell formation, preventing 
thrombosis of the arteries. However, the first-generation DES incorporated non-erodible 
polymers, which were associated to increased risks of death, myocardial infarction, or stent 
thrombosis. In fact animal and human trials provided evidence of arterial inflammation, 
delayer vascular healing witch subsequently led in precipitating stent thrombosis and delayed 
restenosis.
5-8
 These findings stress the need for the development of biodegrdable and more 
biocompatible polymer coatings, which eventually degrade in inert monomers and reduce the 
long-term risks. A wide range of materials has been developed to provide new novel DES by 
using PLGA grades,
9
 poly-l-lactid acid (PLLA),
10
 pullalan hydrogels,
11
 polystyrene-binding 
peptides 
12
 and DNA-containing polyelectrolyte multilayers.
13
 Several therapeutic agents 
including antiprolifirative and immunosuppressive molecules demonstrated impressive 
clinical benefits such as sirolimous , everolimus, zotarolimus , paclitaxel and more recently 
biolimus . Simvastatin can reduce the Low Density Lipoprotein Cholesterol (LDL-C) 
14
 and it 
has been proved efficient to prevent neointimal formation with a positive effect in vascular 
smooth cell proliferation.
15
  
Up to date, spray coating and dip coating have been reported as the main technologies to 
apply drug/polymer layers on the stent strut. In spray coating, a nozzle sprays a drug – 
polymer solution generating droplets of 10 – 15 μm on a stent.16 In the case of dip coating, 
the stent is deposited in the coating solution and subsequently spinned to remove the excess 
material. This process is repeated until the appropriate amount of drug is deposited.
17
 
However, the limitations of these techniques are related to the low yield and the time 
consuming processing. To overcome these drawbacks, inkjet printing technology may serve 
as an alternative approach to coat coronary stents. Inkjet printing is a non-contact technique 
that has been used to dispense pico-quantities of biologically related materials. In recent 
years, inkjet printing received increased attention in pharmaceutical and biomedical industry. 
It is a versatile technology and has been used for the development of various drug delivery 
systems such as polymeric microparticles with controlled dissolution profiles
18
 oral films
19
 
coating of  transdermal microneedles surfaces
20
 and stents coating of drug loaded polymeric 
layers.
21
 Inkjet printing has been used for stent coating due to the high reproducibility and 
accuracy while the capacity to follow patterns of stents with complex design can be proved 
advantageous. In addition, inkjet printing can significantly reduce material waste leading to 
high coating yields by controlling sample aspiration from the dispenser nozzle.   
In inkjet printing, an acoustic pulse ejects droplets from a reservoir through the nozzle either 
by thermal heating or through a piezoelectric system. In thermal inkjet jetting (or bubble-jet) 
the solution in the dispenser is heated locally to form a rapidly expanding vapor bubble that 
ejects an ink droplet. Thermal jetting uses water as a solvent and may therefore impose 
restrictions on the selection of the drugs and polymers that can be printed, although non-
aqueous thermal inks are available. Piezoelectric inkjet printing is based on the deformation 
of some piezoelectric material upon voltage appliance. Specifically, when voltage apply to 
the wall of a piezoelectric crystal, it changes its shape to a pre-ordained direction causing a 
sudden volume change, creating pressure waves which results in a drop being ejected out of 
the orifice.  
Here we report a feasibility study where inkjet-printing technology was used to apply 
biodegradable and biocompatible PXL/PLA and SMV/PLA coatings on stent struts. The 
uniform drug loaded polymeric layers were assessed both in vitro and in vivo for their 
cytotoxicity, biocompatibility and reduction of intra stent restenosis.  
 
1. Materials – Methods  
Materials 
Simvastatin (SMV) and paclitaxel (PCX) were purchased from Sigma – Aldrich and 
from INRESA (Bartenheim, France). Poly(D, L lactide) (Resomer 205) was purchased from 
Evonic (Darmstadt, Germany). Dichloromethane (DCM) was purchased from Sigma-Aldrich 
(UK). Presillion
®
 and Cypher
® 
stents were donated from Abbott Vascular (Abbott, Rungis 
Cedex, France) and Cordis (Johnson & Johnson, Fremont, USA). For the in vitro biological 
evaluation studies , CoCr disks were cut into a cobalt−chromium rod (⌀14.5 mm) accordin  
to  S  standards 5   -1  (Co       , Cr       , o 5 1  , n   5  , Si        bou ht 
 rom   hler-Edelstahl, Germany with a thickness of 3 mm each. 
 
Ink jetting process for DES coating 
For the purposes of the studies ink jetting was conducted by using a Nanoplotter II from 
(GeSim GmbH, Dresden, Germany) fitted with a PicPip 300 dispenser. Solutions of drug and 
polymer were prepared by dissolving the compounds in DCM at a 1:3 (wt/wt) drug/polymer 
ratio (SMV/PLA, PXL/PLA). The technology dispenses and can accurately aspirate aqueous 
and organic solutions. The system consists of the wash station, the dispenser and the dispense 
control system. The amount of aspiration is controlled via an accurate flow sensor while a 
stroboscope ensures that the dispenser ejects the droplets (Fig 1a). Stroboscopic image 
capture provides real-time analysis of pipette performance both before and after sample 
dispensing. Droplet diameter allows estimation of the dispensed volume calculated through 
image analysis. If, for any reason, a sample is not dispensed as instructed (e.g. empty sample 
well), the software logs this and allows for repetition of respective sample printing, thus 
ensuring completion of the task. If there is a failure in droplet ejection the nano-plotter will 
wash the microdispenser and repeat the sample aspiration.  
The drug/polymer solutions were jetted through a piezodriven dispenser (PicPip 300) onto the 
stent strut in the form of fine droplets of approximately 300 pl whereas the stent was gripped 
on a rotating holder, which rotates in a control manner (Fig 1). The dispenser is a 
piezoelectric ceramic that is deformed upon voltage appliance, thus ejecting a droplet from 
the nozzle at a speed 1-5m/s ("drop on demand").  
Due to the complexity of the stent structure and the fact that the stents must rotate during the 
coating process, an algorithm was designed. The coating pattern defined by the algorithm 
where according to it, the dispenser moves longitudinally and vertically on the stent forming 
a perpendicular rectangular shape from one side of the stent to the other jetting one 
droplet/50μm (Fig. 2a). As shown in Fig. 1a he stents are place on a rotating holder where at 
the end of each coating pattern the holder rotates at 45
o
 to coat the next side. The operation 
process is controlled by a stroboscope, which control if the dispenser jets according to the 
standards (Fig. 1b).   
 
Scanning Electron Microscopy 
The quality of the coating was investigated using Scanning Electron Microscopy. The 
samples were attached to aluminum stubs with double-sided adhesive carbon tape, and 
examined using a scanning electron microscope (JEOL JSM 5310LV, SEM) in the low 
vacuum mode at 20 Pa. The working distance was between 35 and 45mm and the image 
captures using Oxford instrument ISIS 300 Autobeam software.  
 
Atomic Force Microscopy (AFM) 
AFM analysis was performed on tapping mode using an easyscan AFM (Nanosurf, Lielestal, 
Switzerland). Tap 190Al-G cantilevers were used (budgetsensor, Sofia, Bulgaria).The drive 
amplitude and the relative set point were chosen in a way that the intermittent force between 
the oscillated tip and the substrate would be minimum and the scan areas was 5μm The 
analysis of the images was performed using SPIP software (Image Metrology, Hørsholm, 
Denmark). 
 
Transition temperature microscopy (TTM) 
TTM was carried using a VESTA
TM
 system equipped with an AN-200 ThermaLever probe 
both from Anasys Instruments (Santa Barbara, USA). This technique is an extension of 
localised thermal analysis (LTA) where probes similar to those used in atomic force 
microscopy (AFM) are employed to provide controlled heating to site-specific areas on a 
sample surface. The voltage was calibrated for temperature by carrying out LTA 
measurements on three standard polymeric samples with known melting points. The 
experiments were carried out from room temperature at a heating rate of 10 °C/s. For each 
sample, an area of 100 x 100 m2 was analysed at a resolution o    μm  Each sample was 
mounted on stainless steel magnetic pucks for analysis. 
Cell vitality and proliferation assay 
This test was performed following the International and European standards (ISO 10993-
5/EN 30993-5) with the human pulmonary microvascular endothelial cell line (HPMEC-
ST1.6R).
22
 The cells were cultured in endothelial cell growth medium MV (Promocell 
GmbH, Heidelberg, Germany) enriched with endothelial cell growth supplement (Promocell 
GmbH, Heidelberg, Germany), streptomycin (0.1 g/L) and penicillin (100 IU/mL), at 37°C in 
a CO2 incubator (CB 150/APT line/Binder, LabExchange, Paris, France) with 5% CO2/ 95% 
atmosphere and 100% relative humidity. The proliferation and vitality of cells were evaluated 
as previously described. Briefly, 6000 cells were seeded on the sterilized CoCr or CoCr/PLA 
disks and incubated for 3 and 6 days, then cell numbers were counted with Coulter Z1 cell 
counter (Beckman Coulter, France) and the cell vitality was evaluated by fluorometric 
analysis (Twinkle LB970TM Berthold) of AlamarBlue
®
 dye (Interchim). Results were 
expressed as percentage compared to the cell growth on tissue-culture polystyrenes surface 
(TCPS). 
 
Immunofluorescence imaging of cell adhesion to disk samples 
The cytoskeletal organization of the HPMEC growing on disk samples at 48 hours after cell 
seeding have been visualized by fluorescent-labeling of F-actin. Briefly, the cells were seeded 
on CoCr disk samples with and without PLA coating. Two days later, cells were fixed in 2% 
paraformaldehyde for 30 minutes at room temperature, permeabilized in a PBS/Triton X-100 
buffer (10 mM PBS, 0.2% Triton) for 15 minutes, and then blocked with 1% bovine serum 
albumin (BSA, Sigma) in PBS. Actin filaments, vinculin and nuclei were stained with 
fluorescein-labelled phalloidin (Sigma) and 4,6-diamidino-2-phenylindole (DAPI) in 
VECTASHIELD
®
 mounting medium (VECTOR laboratories), respectively, according to the 
manu acturer’s protocol  The samples observed by con ocal laser scannin  microscopy 
(LSM710, Zeiss, Germany). 
 
Stent implantation in rat model of in-stent stenosis 
Male Wistar rats (Janvier, Le Gesnest-Saint-Isles, France, n=5), weighing 350 to 400 g, were 
randomly separated into the following groups:  a) negative control with a CoCr bare metal 
stent, b) positive control with a Cypher stent and c) tested groups with SMV/PLA and 
PCX/PLA stents). On the day of implantation,
23
 the rats were anesthetized (ketamine 130 
mg/kg and xylazine 14 mg/kg intraperitoneally) and the abdomen was opened by a sagittal 
incision (NIH Guide for Care and Use of Laboratory Animals). Under microscopic view, the 
abdominal aorta was separated from the vena cava, and small side branches from the aorta 
were ligated. An arteriotomy was made in the proximal part of the 2.5 cm-long isolated 
infrarenal aortic segment. Thereafter, a premounted bare-metal stent (BMS), 2.5 × 14 mm, or 
PLA coated stents, 2.5 × 14 mm, was deployed at its nominal pressure (8 atm). 
 
Histomorphological analysis 
As previously described,
24
 stented arteries were fixed in 4% paraformaldehyde phosphate-
buffered solution, dehydrated, and embedded in methylmethacrylate polymer (Technovit 
 1   new, Heraeus, Germany   Sections   μm thick were cut alon  the entire embedded 
stented vessels, stained with Mayer hematoxylin and eosin and examined under light 
microscopy (Leika DMIL, Germany) with magnification of x5. Images were digitized and 
recorded with the use of a video camera (AxioCam ERc 5s, Carl Zeiss Microscopy, 
Germany). For each stented vessel, 15 sections along the entire length were randomly chosen 
for the morphometric analysis, performed with a computerized digital microscopic 
planimetry algorithm by an independent observer blinded to drug regimen. Cross-sectional 
areas of media, intima, and lumen were measured. Neointimal thickening was expressed as 
the ratio of the neointima area to the media area (n/m). 
 
Cytokines array with PLA 
At 7 days after stent implantation, the animals were anesthetized and heparinized. The stented 
rat aortas were carefully removed, as the inflammatory response is an early event after stent 
deployment. Stented aortic segments were placed in lysis buffer, and the stent was carefully 
removed under optical control. Cytokines array was performed according to the 
manufacturer's instruction (Proteome Profiler Rat Cytokine Array, R&D Systems, France).  
Equal amount o  proteins (    μ   were incubated with a detection antibody cocktail for 1 
hour at room temperature. Then each sample/antibodies mixture was incubated overnight 
with a nitrocellulose membrane with spotted antibodies at 6°C. Bound antibodies were 
visualized by ECL and quantified by densitometric analysis. 
 
Drug loading  
The drug loading for each coated stent was determined by placing the stent in an HPLC vial 
and the addition of 1ml acetonitrile (ACN). The samples were sonicated for 10mins 
(Sonicwave, Cardiff, U.K.) 20min and subsequently the drug amounts were estimated by 
HPLC analysis. The yield of the stent was determined by jetting equal amount of droplets on 
round stainless steel disks for each drug-polymer solution, followed by the addition of 1ml 
acetonitrile.and subsequent HPLC analysis. The following equation was used to calculate the 
final coating yield: 
           
                  
        
       (1)  
 
Dissolution Studies 
The drug-loaded stents (SMV, PCX) were immersed in test tubes containing 2 ml sterilized 
PBS (pH 7.4). The tubes were then incubated in a water-bath shaker at 37
o
C at 120 rpm. The 
incubated PBS in each tube was collected and replaced with fresh buffer system everyday. 
 
HPLC analysis 
Agilent technologies 1200 series with a quaternary pump, an autosampler and a detector set 
at 250nm for simvastatin and 227nm for paclitaxel respectively. The column was an Agilent 
Zorbax Eclipse XDB-C  (    mm × 15  mm, 5 μm particle size  heated at 40oC with a  flow 
rate at 1ml/min injection volumes of 20μl  The Chemstation software calculated the peak area 
of each standard solution and sample automatically. In the case of simvastatin the mobile 
phases consisted of water:formic acid (0.1%) (Phase A) and acetonitrile:formic acid (0.1%) 
(phase B) (A:B = 30:70). For paclitaxel, analysis the mobile phase consisted of 
water:acetonitrile (60:40). 
 
2. Results & Discussion 
Ink jetting of biocompatible polymers 
The selected drug - polymer ratios of the coating formulations were 1:3 (w/w) similar to the 
marketed DES, which subsequently were dissolved, in organic solvents. The jetting process 
optimized by assessing various solvents in order to achieve uniform and reproducible 
coatings. For these reason solvents with high boiling point such as butanone and acetonitrile 
or mixtures with DCM were initially tested. However, this resulted to non-uniform coating 
with uncoated areas on the strut surface due to the slow evaporation of the deposited material, 
which led in droplet accumulation.  The jetting optimization revealed that DCM (Class III) 
was the suitable organic solvent to produce uniform, accurate and reproducible coating. Due 
to the small droplet particle size and the solvent volatility DCM evaporates rapidly (40
o
C 
boiling point) forming the desired drug/polymer layers. However, continuous ink jetting can 
cause a gradual accumulation of polymer at the edge of the nozzle, therefore, Nanoplotter 
was programed to wash the tip periodically with solvent and water solutions. As shown in 
Fig. 1b the particle size of the droplets is observed with a stroboscope, which controls the 
coating process by periodically inspecting the droplet formation from the dispenser. The 
stroboscope can provide qualitative analysis of the droplets generated during the dispensing 
process and provide an approximate estimation of the droplet size.  
Figure 1: a) Image of the piezoelectric dispenser and stent holder of the Nanoplotter device during the coating 
process and, b) stroboscope image of the droplet as ejected from the dispenser 
The efficiency of jetting of coating solutions onto the stent strut depends considerably on the 
tip size, the applied voltage
14
 on the piezoelectric material and the pulse duration (ms). Our 
evaluation showed that tips with 300 pl aqueous droplet volume are suitable for stent coating. 
Tips generating smaller volumes (100 pl) resulted in clogging of the nozzle while larger 
volumes ejected larger droplets, which caused bridge formation between the strut curvatures. 
It has been proved that the fluid volume ejected from the dispenser and as a consequence the 
droplet size is a linear function of the voltage.
25
 For a given coating solution the increase of 
the applied voltage will increase the droplet diameter whereas increase of pulse duration will 
result to a more complicated and periodic behaviour.
26
  It is also worth mentioning that high 
voltages can cause air bubble formation inside the tip when low surface tension liquids are 
used as in the case of organic solvents. The jetting optimization (data not shown) for the 
SMV/PLA and PCX/PLA solutions showed that the applied voltage and pulse vary according 
to the complexity of the stent design whereas combined jetting patterns should be employed. 
Fig 2 illustrates typical coating patterns for ink jetting of a stent surface.   
Figure 2: coating patterns of Cypher® stents a) for large areas of the stent struts, b) for  smaller areas with thin 
struts 
 
Figure 3: SEM images of a) Cypher® stent b) Presillion® stent and c) higher magnification on the surface of 
Cypher® stent 
The Cypher
®
 stent possess more complex design than Presillion
®
, with six circumferential 
cells and ultra-thin links connecting the cells.  These curvy ultra-thin stent links were more 
difficult to coat as the droplets tended to accumulate at the edges. Therefore, the links were 
targeted separately after the first coating (Fig. 2b). The applied voltage and pulse duration for 
the wider strut surfaces were 100V and 60μsec respectively (Fi  2a) while for the thin parts 
  V and   μsec (Fi  2b).  
The voltage reduction facilitated the formation of smaller droplet size without any splashing 
and thus reduced material losses.The quality of stent coating is very important as affects the 
release profile of the therapeutic agent while smooth surface coatings can significantly 
decrease the injury of blood vessel. Tepe et al. evaluated different peripheral stents and found 
that smoothing the surface results to a clear decrease of their thrombogenicity.
27
 Furthermore, 
uniform coating without cracks and bridges is required for a homogenous release across the 
total stent strut. The SEM images in Fig. 3 showed smooth and uniform drug/polymer layers 
for the obtained coatings irrespectively of the stent design and without any bridges forming 
between the struts. The coating efficiency of ink jetting was assessed in terms of the obtained 
yields.  As show in Table 1, ink jetting of the Presillion
®
 stent provided far better yield 
compared to Cypher
®
. This is probably due to the less complex design of Presillion
®
 although 
both stents have a closed–cell design. Also, the reproducibility for Cypher® is ±6.49% and 
±4.05% for Presillion
®
 which is acceptable from the industry. 
 
Atomic Force Microscopy (AFM) 
AFM images of coated stent with SMV/PLA and PCX/PLA are shown in Fig. 4. In both 
mixtures, the coating is homogenous without any phase separation. Roughness analysis 
showed that the roughness of PCX/PLA and SMV/PLA is 53.5nm and 85nm respectively 
indicating that the coating is almost flat. More importantly similar studies of AFM and 
confocal Raman microscopy showed that the estimated roughness of the marketed Cypher® 
stents is approximately 2μm rendering the stents produced by inkjet printing more 
advantageous.
28
 It is worth mentioning that the bright areas in phase image of PCX/RES have 
been created due to the stronger interaction forces between the AFM tip and the surface when 
the tip enters inside the pores. These pores in both topographic images is a common are 
usually observed in solvent casting polymer layers  or stent coatings and are formed due to 
solvent evaporation. 
 
 
Figure 4: Topographic (left) and Phase (right) AFM images of a) PCX/PLA and b) SMV/PLA 
 
TTM Analysis 
Fig. 5 shows a typical TTM analysis, which involves placement of the probe at a chosen 
location and the application of a scanning voltage profile whilst simultaneously monitoring 
the probe deflection.  
 
 Figure 5: TTM maps and histograms (right) of a) pure sprayed PLA, b) pure sprayed PCX, c) pure sprayed 
SMV d) PCX/PLA mixture and e) SMV/PLA mixture 
Due to thermal expansion of the material being heated, the probe deflects upwards until a 
thermal event occurs, such as melting, where probe penetration is observed as downwards 
deflection due to the material softening. As expected the initial analysis of plain PLA coating 
layers, showed a mean value of the glass transition
29
 at 53.9
o
C while the Gaussian 
distribution in Fig. 5a indicates a single phase. As shown in fig. 5b for coated bulk APIs the 
TTM analysis revealed a gaussian distribution with a mean value of 148
o
C for PCX which is 
close to the experimental value reported in literature (153
o
C).
30
 However, in the case of 
SIMV a bimodal distribution can be observed where the first broad peak lies close to the Tg 
of SIMV (35
o
C)
31
 and the second stronger peak at 74
o
C, which corresponds to crystalline 
drug (Fig. 5c).  
In the case of PXL/PLA coated layers TTM analysis showed a unimodal distribution with a 
single Tg at 78
o
C indicating the homogeneity of the binary mixture (Fig. 5d). The observed 
Tg lies between the PXL and PLA Tgs suggesting that PXL is molecularly dispersed in the 
polymer matrix. Similar results with a single Tg at 44
o
C were observed for the SMV/PLA 
coatings with SMV being molecularly dispersed in the polymer matrix (Fig. 5e). The results 
are in agreement with the AFM observations, which showed that there is no phase separation 
between the components. It is worth mentioning that the distribution is negatively skewed in 
the case of PCX/PLA coatings due to the higher concentration of polymer, which shifts the 
Tg of the mixture to lower values. 
 
Cell vitality and proliferation assay 
In order to investigate the cytocompatibility of the stent coating polymer, cell vitality and 
proliferation assay were implemented. Several studies have been reported to investigate the 
proliferation, morphology and attachment of different types of cells on various drug delivery 
systems or medical implants where all confirmed the biocompatibility of PLA.
32, 33
  
 
Figure 6: Graphs of HPMEC vitality and proliferation on CoCr, Resomer-Cocr and TCPS substrates 
 
Yet, the use of organic solvent to dissolve the compounds could have a detrimental effect 
re ardin  coatin ’s biocompatibility due to the presence o  any residues. The results showed 
a significant difference of cell proliferation or vitality between CoCr disk groups and TCPS 
(Fig. 6). Although the vitality rate and proliferation level were slightly lower on disk samples 
(~80%) than that on TCPS (100%), there is no significant difference between CoCr and 
CoCr/PLA samples. Thus, it was concluded that PLA coatings did not decrease the vitality or 
proliferation of cells, and confirmed the in vitro biocompatibility of the polymeric carrier. In 
addition, the results provide strong evidence that DCM has been removed and there are no 
any solvent residues in the coated layers, which would result in reduced cell viability. 
 
Immunofluorescence imaging and cell adhesion  
Concerning the cell adhesion at 48 hours after cell seeding, cells were well spreading over 
non-coated CoCr surface with a normal cytoskeleton. As shown in Fig. 7a the cells appear to 
have long green bundles of stress fibres composed of actin filaments. In Fig. 7b the cells, on 
the PLA coated CoCr surface, are wide-spreading with well-defined actin filaments showing 
a similar morphology to those of the non-coated CoCr disks. The organization of the 
cytoskeleton on PLA coated CoCr disks confirmed the excellent cell-substrate adhesion. 
 
Figure 7: Fluorescence microscopy images on HPMEC on CoCr (left) and on CoCr/Resomer (right) samples 
Cytokines array with PLA 
Further studies investigated the levels of several cytokines and inflammatory adhesion 
molecules in stented aortic segments 7 days after stent deployment. The implanted stents 
were coated only with the PLA polymer without containing any anti-proliferative agent, as 
the aim was only to evaluate the in vivo toxicity of the PLA coating. The protein array 
revealed no significant variation of several immunogenic and chemo-attractive cytokines 
expression, such as interleukin 6 and tumour necrosis factor-α, as well as adhesive molecules 
expression such as intercellular adhesion molecule. Fig. 8 illustrates the recorded levels of the 
investigated molecules between the implanted PLA coated stents and the controls (n = 3). 
The results obtained from the in vivo implantation demonstrated that the PLA coatings did 
not increase the inflammatory response after stent implantation, comparing with bare metal 
stent. Nevertheless, further studies are required to evaluate the inflammatory response of the 
drug coated stents.  
 
Figure 8: Comparison Cytokines for PLA and control coated CoCr disks. 
Histomorphological analysis 
As shown in Fig. 9 the DES developed by inkjet printing implanted in Male Wistar rats for 
comparison with BMS (negative control) and Cypher stents (positive control).  Fig. 10 shows 
the histomorphological analysis of the stented aortic sections for the implanted stents  
 
Figure 9: Stent implantation in Male Wistar rats: a) infra-renal aorta exposition, b) aortic cross-clamping and 
transverse aortotomy, c) stent insertion, d) infrarenal stenting and closure of the aortotomy. 
 
As it can be seen from Fig. 11 the analysis revealed the same reduction in neointima 
formation between the plain PLA coated stent compared to the negative control BMS and 
confirmed the in vitro cell proliferation results.  
 
 
Figure 10: Images of the ISR for the BMS, Positive Control stent, SMV and PCX coated stent. 
 
The results also demonstrate lower ISR of the PCX/PLA (n/m 0.67) compared to BMS (n/m 
0.73), which demonstrates the clinical effect of PXL from inkjet printing stents. In addition 
PXC/PLA stents show a slightly higher ISR values compared to the marketed Cypher stents 
(positive control). However this is not uncommon as
34
 PXL demonstrated significant 
reduction in late lumen loss, diameter stenosis and neointimal hyperplasia but not a dramatic 
reduction in the incidence ISR compared to sirolimus.   
As shown in Fig. 11 an unexpected ISR (1.02) reduction was observed for the SMV/PLA 
stents compared to the negative control. SMV demonstrated encouraging results in the past 
by reducing neointimal formation in the human saphenous vein, inhibiting VSMC 
proliferation and migration.
35, 36
 However there are cases where SMV demonstrated 
insufficient performance and did not facilitate any ISR reduction after stent implantation.
37, 38
 
In this case, further investigation is required and perhaps an increase of the SMV/PLA ratio 
could provide better ISR results. Nevertheless, the obtained experimental findings showed 
that inkjet printing is a robust technology, which can be employed for the development of 
DES.  
 Figure 11: Quantification of the ISR for BMS, Positive Control stent, SMV and PCX coated stent 
 
Drug Release  
The in vitro drug release rates from the stent strut are important for the development of DES 
and can be controlled by adjusting the drug/polymer ratio. PLA has been extensively used to 
control the drug release mainly in the form of nanoparticles but it has also been implemented 
in various biomedical applications.
39
 The cumulative drug release profiles of SMV and PCX 
are represented in Figure 11.  
 
Figure 12: Dissolution profiles of SMV/PLA (1:3 wt/wt) and PCX/PLA (1:3 wt/wt) coated stents with 1  μ  o  
drug substances (n=3) 
As it can be seen both drugs exhibit burst release for the first 5 days, followed by slower 
release rates. This is not uncommon in DES and it has been observed in similar studies.
35, 40
 
As it can be seen the burst release is of the magnitude of 22% and 35 % for PCX and SMV 
respectively. At the end of the study period, 80% of SMV and 75% of PXC were released. 
The increased burst release of SMV compared to PCX is associated to the phase separation of 
the drug from the polymer. In contrast PCX interacts with PLA forming a homogenous 
mixture, as confirmed by AFM and TTM, which in turn delays the release rates. After the 
initial burst release both drugs followed a first order release for another 25 days. However, 
we anticipate that the in vivo performance of PXC and SMV release rates will substantially 
differ from those shown in Fig. 11.  Nevertheless, the drug release studies demonstrated a 
sustained release pattern for both types of DES.  An important aspect of ink jetting is that by 
adjusting the drug/polymer ratio in the coating solution or by using different polymer grades 
the stent release profiles can be and the applied drug substance amounts tuned accordingly to 
the patient needs.  
 
Conclusion  
In this study, inkjet-printing technology has been used successfully to apply uniform and 
reproducible PCL/PLA and SMV/PLA coatings. The drug/polymer compositions did not 
have any influence on the coating uniformity while the obtained yields were found to be 
dependant on the stent design. The in vitro evaluation showed excellent polymer cell 
proliferation and cell adhesion. The stent implantation in animal models demonstrated the 
absence of inflammatory response and the reduction of ISR similar to marketed bare metal 
and drug eluting stents.  Overall, inkjet-printing technology can be effectively used for the 
optimization of robust drug eluting stents and the application of wide range drug/polymer 
uniform layers with controlled drug release patterns.  
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